Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > SHORT INTEREST - VERY SMALL IF ANY

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Feb 02, 2023 10:55am

143 Views

Post# 35262236

RE:RE:SHORT INTEREST - VERY SMALL IF ANY

inthno wrote: If the number of oustanding shares is correct at 61,330,000 then that is an increase of over 2 million shares as shown from the last corporate presentation.which shows the company is still activley using the ATM which is a necessity one would think,

Financial data as of Sep. 30, 2022, Share Count data as of Nov. 3, 2022, and Market Cap. data as of Jan. 19, 2023
Exchanges Nasdaq: ONCY / TSX: ONC
Market Cap. Approx. $113M
Cash & Equivalents CDN $32.4M (USD $24M)
Based on FX as of Nov. 8, 2022
Shares Outstanding 59,028,688
Fully Diluted 64,388,508